Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its ...

In a deal worth up to $840 million, Third Arc Bio Inc. is licensing Adagene Inc.’s Safebody technology platform to generate ...

A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple ...

Withings SA received U.S. FDA clearance for Beamo, its health check-up tool designed to monitor heart and lung function. Described as the ‘thermometer of the future’, Beamo combines the sensors of an ...

The U.S. Environmental Protection Agency has moved to relax reporting requirements for perfluoroalkyl and polyfluoroalkyl substances used in a variety of applications, including medical devices.

Biopharma companies focused on infectious disease extended their stock recoveries through the third quarter (Q3), with the BioWorld Infectious Disease Index closing October up 28.98%. The gain marks a ...

A team of five members of the U.S. FDA staff published a review of the use of AI in health care and concluded that while ...

Biopharma happenings, including deals and partnerships, and other news in brief: Century, Charm, Daiichi, Day One, Decoy, Flightpath, General Proximity, Kaken, Mersana, Metsera, Novo Nordisk, Numab, ...

During the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scientists from Plexium Inc. presented the identification of a new class of potent, selective, cereblon ...

Fifteen years since the first patient was treated, and after being ditched by two companies, the EMA is recommending approval of Waskyra (etuvetidigene autotemcel), the first gene therapy for treating ...